Premium
Evolving trends in the treatment of low‐risk myelodysplastic syndromes: immunomodulation and beyond—9th European Hematology Association Congress Geneva, Switzerland, 10–13 June 2004
Author(s) -
Fenaux P.,
Bennett J. M.,
Bowen D. T.,
Knight R. D.,
List A. F.
Publication year - 2007
Publication title -
transfusion medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.471
H-Index - 59
eISSN - 1365-3148
pISSN - 0958-7578
DOI - 10.1111/j.1365-3148.2006.00681.x
Subject(s) - hematology , medicine , myelodysplastic syndromes , hematologic neoplasms , oncology , family medicine , cancer , bone marrow
summary The 9th European Hematology Association Congress, held in Geneva, Switzerland, from 10 through 13 June 2004, offered a number of educational programmes that focused on myelodysplastic syndromes (MDS). This report will summarize the material presented at the educational symposium entitled ‘Evolving Trends in the Treatment of Low‐Risk MDS: Immunomodulation and Beyond’. The overview of the presentations includes a comparative review of the classification systems for MDS; a discussion of treatment strategies and management issues for patients in lower risk disease categories; a description of a novel class of immunomodulators, the IMiDs ® , and a presentation of updated data from clinical trials of the IMiD compound, lenalidomide, in the treatment of MDS.